Auris Medical Company

Auris Medical are dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus and restore balance.

Auris Medical is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo.

Company has additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.
Technology: P4 Medicine
Industry: P4 Medicine
Headquarters: Basel, Basel-Stadt, Switzerland
Founded Date: 6-25
Employees Number: 11-50
Funding Status: IPO
Investors Number: 6
Total Funding: $73.5M
Estimated Revenue: $1M to $10M
Last Funding Type: Post-IPO Debt

Visit Website
ear@aurismedical.com
Register and Claim Ownership